RxDoctor Payments DataLook up a doctor →

Dara Botts

Family · Lebanon, TNNPI 1982826004

Payments from drug & device makers

$47,222in general payments, 2019–2025

Across 578 payments — averaging $81.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$31K
  • Zealand Pharma US, Inc.$5K
  • Corcept Therapeutics$2K
  • AstraZeneca$987
  • Lilly USA, LLC$885
  • BETA Bionics, Inc.$686
  • plus $6K from 51 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk139$31,348
Zealand Pharma US, Inc.20$5,129
Corcept Therapeutics28$1,990
AstraZeneca(2 entities)36$987
Lilly USA, LLC50$885
BETA Bionics, Inc.14$686
Amgen(2 entities)39$624
Sanofi-aventis U.S. LLC14$549
Mannkind Corporation22$431
Xeris Pharmaceuticals, Inc.18$429
Insulet Corporation13$351
AbbVie20$327
Medtronic11$312
Cequr Corporation3$273
Abbott14$272
Esperion Therapeutics, Inc.7$263
Vistapharm, Inc.13$179
Dexcom, Inc.6$157
Novartis9$157
Radius Health, Inc.8$152
Boehringer Ingelheim8$133
Ascensia Diabetes Care US Inc.3$123
Bayer6$112
Amarin Pharma, Inc.6$103
Otsuka America Pharmaceutical, Inc.5$99
Arbor Pharmaceuticals, Inc.6$98
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$97
Averitas Pharma Inc.3$83
Antares Pharma, Inc.5$82
Biohaven Pharmaceutical Holding Company Ltd.4$77
IBSA Pharma Inc.3$50
Tandem Diabetes Care, Inc.3$50
Sequel Med Tech, LLC2$47
Biohaven Pharmaceuticals, Inc.3$43
Pfizer2$37
Azurity Pharmaceuticals, Inc.2$36
Axsome Therapeutics, Inc.2$36
Exact Sciences2$35
Jazz Pharmaceuticals Inc.2$34
Lundbeck LLC2$29
Nevro Corp.1$27
Teva Pharmaceuticals USA, Inc.2$27
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$23
Takeda Pharmaceuticals U.S.A., Inc.2$23
Nestle Healthcare Nutrition Inc.1$22
Alkermes, Inc.1$21
Sumitomo Pharma America, Inc.1$21
Kyowa Kirin, Inc.1$17
Amphastar Pharmaceuticals, Inc.1$17
Clarus Therapeutics Inc.1$17
Ultragenyx Pharmaceutical Inc.1$16
Ascendis Pharma Endocrinology Inc1$16
Amneal Pharmaceuticals LLC1$16
Shield Therapeutics Inc1$16
Alfasigma USA, Inc.1$15
Adlon Therapeutics L.p.1$14
Merck1$12

How this compares

$47,222 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee →

Medicare billing

Part B allowed, 2024
$87,574
Medicare patients
305
Services billed
1,580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family in Lebanon

See the full list for Tennessee →

Where these figures come from

Is this you, or does something look wrong? →